Although cytotoxic CD8+ T lymphocytes (CTLs) are essential for anti-tumour immunity, they are frequently dysfunctional in tumours1. Cytokines that sustain CTL activity are attractive for cancer immunotherapy, but avoiding inflammatory toxicity remains a challenge for their clinical use2. Here we show that expression of a CTL signature is strongly associated with IL27 expression in human and mouse tumours. In mice, IL-27 acts directly on tumour-specific CTLs to promote their persistence and effector function in the tumour microenvironment. Moreover, treatment with inducible IL-27 overexpression or a half-life-extended IL-27 protein in vivo is well tolerated, induces regression of established tumours, drives an enhanced cytotoxic program in anti-tumour CTLs and synergizes with PD-L1 blockade. In patients with cancer who were treated with anti-PD-1/PD-L1 therapy, high expression of IL-27 correlates with a favourable clinical response, and IL-27 supports human CTL function during chronic a

YouTube video by Indisputable with Dr. Rashad Richey

Hashimoto et al. show that CD4 CTLs expand around age 100 and form large private clones without exhaustion. These cells exhibit stepwise differentiation and cytokine plasticity, suggesting adaptive re...

Whether cytotoxic T lymphocytes (CTLs) exert protumorigenic effects remains elusive. Huang et al. reveal that macrophages cross-present to clonally expanded CD103+ CTLs in the pericancerous area in he...